Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
1.490
+0.280 (23.14%)
Jul 21, 2026, 1:37 PM EDT - Market open
Dyadic International Revenue
Dyadic International had revenue of $1.11M in the quarter ending March 31, 2026, with 182.28% growth. This brings the company's revenue in the last twelve months to $3.81M, up 7.13% year-over-year. In the year 2025, Dyadic International had annual revenue of $3.09M, down -11.59%.
Revenue (ttm)
$3.81M
Revenue Growth
+7.13%
P/S Ratio
11.58
Revenue / Employee
$761,546
Employees
5
Market Cap
54.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.09M | -405.04K | -11.59% |
| Dec 31, 2024 | 3.50M | 596.58K | 20.58% |
| Dec 31, 2023 | 2.90M | -31.49K | -1.07% |
| Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
| Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
| Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
| Dec 31, 2019 | 1.68M | 385.63K | 29.77% |
| Dec 31, 2018 | 1.30M | 537.03K | 70.81% |
| Dec 31, 2017 | 758.42K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Metagenomi Therapeutics | 22.33M |
| Radiopharm Theranostics | 10.86M |
| CervoMed | 2.09M |
| Hyperion DeFi | 1.04M |
| Mereo BioPharma Group | 500.00K |
| aTyr Pharma | 190.00K |
| INmune Bio | 50.00K |
| Impact BioMedical | 39.00K |
DYAI News
- 5 days ago - Dyadic expands bio-industrial pipeline with new industrial enzyme program - TheFly
- 5 days ago - Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program - GlobeNewsWire
- 14 days ago - Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential - GlobeNewsWire
- 22 days ago - Dyadic International allowed claims by Japan Patent Office - TheFly
- 22 days ago - Dyadic Expands IP Protection and Business Development Activities in Japan - GlobeNewsWire
- 4 weeks ago - An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets - Newsfile Corp
- 4 weeks ago - Dyadic International Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Dyadic International Proxy statement: Proxy filing - Filings